Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus

Keyphrases

• Adult Patients 20%
• Adverse Events 20%
• Anemia 20%
• Antiretroviral Therapy 60%
• Blood Transfusion 20%
• Chronic Hepatitis C 100%
• Creatinine 20%
• Cytomegalovirus 20%
• Donor Age 20%
• FFPE Tissue 20%
• Fibrosis 60%
• Fibrosis Progression 20%
• Fibrosis Stage 20%
• Gallbladder 20%
• Graft Survival 40%
• Granulocyte Colony-stimulating Factor (G-CSF) 20%
• Hepatic Decompensation 40%
• Hepatitis C Virus 100%
• Hepatitis C Virus Recurrence 20%
• Histopathology 20%
• Hospitalization Rate 20%
• IL28B 40%
• IL28B Genotype 20%
• Improved Survival 20%
• Inflammation 20%
• Inpatient Treatment 20%
• Leukopenia 20%
• Liver Biopsy 20%
• Liver Complications 20%
• Liver Histology 20%
• Liver Transplant Recipients 100%
• Low Accelerating Dose Regimen 100%
• Medical Records 20%
• Native Liver 20%
• Novel Technique 20%
• Online Treatment 20%
• Patient Survival 60%
• Pegylated Interferon alfa-2a 20%
• Plasma Viral Load 20%
• Post-liver Transplant 40%
• Ribavirin 20%
• Rs12979860 20%
• Sepsis 20%
• Serious Adverse Events 20%
• Thrombocytopenia 20%
• Total Bilirubin 40%
• Treatment Discontinuation 20%
• Treatment-related 20%
• Treatment-related Mortality 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 33%
• Alpha2a Interferon 16%
• Anemia 16%
• Antiviral Therapy 50%
• Bilirubin 33%
• Creatinine 16%
• Cytomegalovirus 16%
• Decompensated Liver Cirrhosis 33%
• Fibrosis 83%
• Granulocyte Colony Stimulating Factor 16%
• Hepatitis C Virus 100%
• Inflammation 16%
• Leukopenia 16%
• Peginterferon Alpha 16%
• Recurrent Disease 16%
• Ribavirin 16%
• Sepsis 16%
• Thrombocytopenia 16%